SG11202009549YA - Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy - Google Patents
Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapyInfo
- Publication number
- SG11202009549YA SG11202009549YA SG11202009549YA SG11202009549YA SG11202009549YA SG 11202009549Y A SG11202009549Y A SG 11202009549YA SG 11202009549Y A SG11202009549Y A SG 11202009549YA SG 11202009549Y A SG11202009549Y A SG 11202009549YA SG 11202009549Y A SG11202009549Y A SG 11202009549YA
- Authority
- SG
- Singapore
- Prior art keywords
- phospholipid
- methods
- same
- cancer therapy
- targeted cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655659P | 2018-04-10 | 2018-04-10 | |
| PCT/US2019/026853 WO2019200017A1 (en) | 2018-04-10 | 2019-04-10 | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009549YA true SG11202009549YA (en) | 2020-10-29 |
Family
ID=68164618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009549YA SG11202009549YA (en) | 2018-04-10 | 2019-04-10 | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210163513A1 (en) |
| EP (1) | EP3773544A4 (en) |
| JP (1) | JP7402172B2 (en) |
| KR (1) | KR20200140835A (en) |
| CN (1) | CN112272556B (en) |
| AU (2) | AU2019251483B2 (en) |
| BR (1) | BR112020020759A2 (en) |
| CA (1) | CA3095515A1 (en) |
| EA (1) | EA202092369A1 (en) |
| IL (2) | IL277875A (en) |
| MA (1) | MA52247A (en) |
| MX (1) | MX2020010741A (en) |
| SG (1) | SG11202009549YA (en) |
| WO (1) | WO2019200017A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3229810T1 (en) | 2014-11-17 | 2021-01-29 | Cellestar Biosciences, Inc. | Phospholipid ether analogs as cancer-targeting drug vehicles |
| CA3150991A1 (en) * | 2019-09-12 | 2021-03-18 | Cellectar Biosciences, Inc. | Phospholipid ether conjugates as cancer-targeting drug vehicles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4132344A1 (en) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | METHOD FOR PRODUCING A MEDAL FOR ORAL OR TOPICAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS |
| DE4408011C1 (en) * | 1994-03-10 | 1995-11-02 | Max Delbrueck Centrum | Liposomes for tumour therapy |
| US8022235B2 (en) * | 2007-06-01 | 2011-09-20 | Cellectar, Inc. | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use |
| CN103944903B (en) | 2014-04-23 | 2017-02-15 | 福建联迪商用设备有限公司 | Multi-party authorized APK signature method and system |
| SI3229810T1 (en) * | 2014-11-17 | 2021-01-29 | Cellestar Biosciences, Inc. | Phospholipid ether analogs as cancer-targeting drug vehicles |
| EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
| ES2952867T3 (en) * | 2016-06-14 | 2023-11-06 | Cellectar Biosciences Inc | Phospholipid ether analogues for the identification and isolation of circulating tumor cells |
| CA3150991A1 (en) * | 2019-09-12 | 2021-03-18 | Cellectar Biosciences, Inc. | Phospholipid ether conjugates as cancer-targeting drug vehicles |
-
2019
- 2019-04-10 JP JP2020555450A patent/JP7402172B2/en active Active
- 2019-04-10 SG SG11202009549YA patent/SG11202009549YA/en unknown
- 2019-04-10 US US17/044,757 patent/US20210163513A1/en active Pending
- 2019-04-10 EP EP19784548.0A patent/EP3773544A4/en active Pending
- 2019-04-10 WO PCT/US2019/026853 patent/WO2019200017A1/en unknown
- 2019-04-10 KR KR1020207030504A patent/KR20200140835A/en not_active Application Discontinuation
- 2019-04-10 MX MX2020010741A patent/MX2020010741A/en unknown
- 2019-04-10 EA EA202092369A patent/EA202092369A1/en unknown
- 2019-04-10 MA MA052247A patent/MA52247A/en unknown
- 2019-04-10 CN CN201980036064.8A patent/CN112272556B/en active Active
- 2019-04-10 CA CA3095515A patent/CA3095515A1/en active Pending
- 2019-04-10 BR BR112020020759-4A patent/BR112020020759A2/en unknown
- 2019-04-10 AU AU2019251483A patent/AU2019251483B2/en active Active
-
2020
- 2020-10-08 IL IL277875A patent/IL277875A/en unknown
-
2021
- 2021-11-05 AU AU2021261949A patent/AU2021261949A1/en not_active Abandoned
-
2023
- 2023-07-04 IL IL304245A patent/IL304245A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200140835A (en) | 2020-12-16 |
| CA3095515A1 (en) | 2019-10-17 |
| US20210163513A1 (en) | 2021-06-03 |
| MA52247A (en) | 2021-02-17 |
| AU2019251483A1 (en) | 2020-10-15 |
| EP3773544A1 (en) | 2021-02-17 |
| BR112020020759A2 (en) | 2021-01-19 |
| CN112272556A (en) | 2021-01-26 |
| AU2019251483B2 (en) | 2021-08-05 |
| EA202092369A1 (en) | 2021-01-26 |
| EP3773544A4 (en) | 2022-04-13 |
| IL277875A (en) | 2020-11-30 |
| AU2021261949A1 (en) | 2021-12-02 |
| JP2021521169A (en) | 2021-08-26 |
| JP7402172B2 (en) | 2023-12-20 |
| CN112272556B (en) | 2023-12-19 |
| WO2019200017A1 (en) | 2019-10-17 |
| IL304245A (en) | 2023-09-01 |
| MX2020010741A (en) | 2020-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| EP3574018A4 (en) | Tumor targeting conjugates and methods of use thereof | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL274246A (en) | Diagnostic and therapeutic methods for cancer | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| IL273071A (en) | Diagnostic and therapeutic methods for cancer | |
| IL274837B1 (en) | Combination therapy for the treatment of cancer | |
| ZA202005847B (en) | Cancer therapy | |
| IL277854A (en) | Antibody-drug conjugates and their uses for the treatment of cancer | |
| IL304245A (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| EP3347010A4 (en) | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| IL280830A (en) | Conjugates for use in methods of treating cancer | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| IL263905A (en) | Combination therapy of cancer | |
| IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
| EP3999092A4 (en) | Combination cancer therapy agents and methods | |
| EP3737373A4 (en) | Methods and combination therapy to treat cancer | |
| EP3864039A4 (en) | Neuroendocrine cancer targeted therapy | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer | |
| EP4041718A4 (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| IL274866A (en) | Compositions and methods for cancer therapy | |
| EP3684401A4 (en) | Therapeutic combination and method for treating cancer |